HUM Stock Recent News
HUM LATEST HEADLINES
U.S. equities edged higher at midday as the market considered the impact of the Republican tax and spending bill that passed by the narrowest of margins this morning. The Nasdaq, Dow Jones Industrial Average, and S&P 500 all rose.
Shares of Humana (HUM) and other health insurers fell Thursday after the Centers for Medicare & Medicaid Services said it plans to take a more "aggressive" approach to auditing Medicare Advantage plans.
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. (“Humana” or the “Company”) (NYSE: HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
CMS will begin to audit all eligible MA contracts every payment year, the federal agency said Wednesday.
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOUISVILLE, Ky.--(BUSINESS WIRE)--The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, is proud to announce that Tiffany Benjamin, the foundation's CEO, has been named to the inaugural TIME100 Philanthropy list, celebrating the singular figures shaping the future of giving. “I am deeply honored to be recognized by TIME100 Philanthropy for the work of the Humana Foundation and our nonprofit partners in advancing health equity for underserved and marginalized communi.
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE: HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE: HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.